QCG
LPCN icon

Quadrant Capital Group’s Lipocine LPCN Stock Holding History

Quadrant Capital Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-124
Closed -$7K – 2186
2017
Q4 		$7K Hold
124
– – ﹤0.01% 1344
2017
Q3 		$8K Hold
124
– – ﹤0.01% 1274
2017
Q2 		$8K Hold
124
– – ﹤0.01% 1179
2017
Q1 		$8K Buy
124
+31
+33% +$2.01K ﹤0.01% 1162
2016
Q4 		$5K Buy
+93
New +$5.89K ﹤0.01% 1244

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Quadrant Capital Group's LPCN Position: Q1 2018 in Review

Quadrant Capital Group sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 124 shares — an estimated $7K sold.

Quadrant Capital Group first reported a position in LPCN in Q4 2016 and held it in 5 quarters. The position peaked at $8K in Q3 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • Quadrant Capital Group reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • Quadrant Capital Group sold 124 Lipocine shares in Q1 2018, an estimated $7K.
  • Quadrant Capital Group first reported a position in Lipocine in Q4 2016 and held it in 5 quarters.
  • Quadrant Capital Group's Lipocine position peaked at $8K in Q3 2017.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Quadrant Capital Group's 13F filing for Q1 2018, filed 10 May 2018.